MedPath

Withdrawal of Pharmacological Treatment in Patients Responding to Cardiac Resynchronization Therapy: (REMOVE)

Phase 1
Recruiting
Conditions
Heart Failure
MedDRA version: 20.0Level: LLTClassification code: 10019279Term: Heart failure Class: 10007541
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Registration Number
CTIS2023-504946-70-00
Lead Sponsor
Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients who have received cardiac resynchronization therapy at least one year before for left bundle branch block and LVEF <40% of non-ischemic origin., Current LVEF = 50% and normal volumes in two studies consecutive echocardiograms, separated by at least 3 months, with the last performed in the previous six months., NYHA functional class I-II, Absence of admissions for heart failure in the last year, NT-proBNP <450 pg/mL in patients in sinus rhythm or <900 pg/mL in patients with atrial fibrillation, in the previous 6 months., Pharmacological treatment with beta-blockers, ACEIs/ARA II/ARNI with or without ARM, Normally functioning cardiac resynchronization therapy device with >95% pacing, Older than 18 years, Patients who have given their written informed consent.

Exclusion Criteria

Previous episode of sustained ventricular tachycardia/sudden death recovered/appropriate discharge (in case of being a carrier of implantable cardioverter-defibrillator associated with cardiac resynchronization therapy), Uncontrolled arterial hypertension (figures >140/90 mmHg)., Need for the use of beta-blockers at the medical discretion of other indications such as heart rate (HR) control in atrial fibrillation (in the absence of ablation of the atrioventricular node) or to control other supra or ventricular arrhythmias., Severe valve disease., Diabetics or hypertensives with microalbuminuria or proteinuria, Renal failure with creatinine clearance < 30 ml/min/1.73m2., Fertile women who do not use contraception or are sterilizedsurgically; pregnant or lactating women., Currently participating in a clinical trial or have participated in the previous 30 days

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath